Description

QuidelOrtho Corporation’s VITROS Momentum Is Building and It Could Be a Game Changer!

QuidelOrtho recently reported its third-quarter 2025 financial results, delivering a mix of strengths and challenges that shape the company’s current investment appeal. First, the positives. QuidelOrtho demonstrated a robust underlying performance with organic sales growth of 5%, excluding COVID-related revenues and the divestment from the U.S. donor screening business. This growth signifies the strength and resilience of its diversified global diagnostics portfolio. The company showcased improvements in its adjusted EBITDA, which rose to 25% of sales, highlighting effective cost control measures that led to over $140 million in cost savings. Investments in key strategic areas and advancements in research and development, such as the clearance of the new VITROS high-sensitivity troponin assay, position QuidelOrtho for sustained long-term growth. The expansion of this cardiac panel is expected to enhance their competitive edge in the market. Geographically, growth outside the U.S.